Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Cravatex
Cravatex Ltd. (Cravatex) is a market leader in providing fitness equipment distribution under its brand Proline Fitness and represents the 100-year old Italian brand, FILA, in India. Cravatex has recently acquired sub-license to distribute the products of FILA in the United Kingdom (UK) and Ireland. The company has also been forming strategic partnerships with various health club chains in India such as Talwalkars and Gold Gym in the fitness equipment segment. Cravatex is trading at an attractive 9.8x PE and 0.5x EV/Sales on FY2014E. We recommend Buy on Cravatex with a target price of `800, based on target PE of 12x and implied EV/Sales of 0.6x for FY2014E
BUY
CMP Target Price
Investment Period
`655 `800
12 Months
Investment rationale
Strategic partnership and organic growth to drive 45% growth
Owing to robust organic growth and strategic partnerships the net revenue for the fitness equipment segment is expected to grow at 45% CAGR over FY2011-14E. Cravatex is a market leader in fitness equipment distribution and operates through a wide network of 51 retail stores across India. The company has recently entered into strategic partnership with reputed health club chains in India such as Talwalkars and Gold Gym to provide them with high-quality equipment and customer service.
Key financials
Cravatex FY2011 FY2012E FY2013E FY2014E Net sales OPM (` cr) (%) 93 7.4 230 301 361 5.7 4.3 5.8 PAT (` cr) 6 9 11 17 EPS (`) 25 36 42 67 ROIC (%) 15 21 18 24 P/E (x) 26.5 18.1 15.5 9.8 P/BV EV/ EBITDA EV/ Sales (x) (x) (x) 7.1 27.1 2.0 5.3 4.0 2.9 14.7 14.9 9.1 0.8 0.6 0.5
Twinkle Gosar
Tel: 022- 3935 7800 Ext: 6848 Gosar.twinkle@angelbroking.com
Investment arguments
Strategic partnership and organic growth to drive 45% growth
Cravatex is a market leader in fitness equipment distribution through its brand Proline Fitness. The company distributes products of Johnson Health Tech, the third largest fitness company in the world. Cravatex operates through a wide network of 51 retail stores across India. The company has recently entered into strategic partnership with reputed health club chains in India such as Talwalkars and Gold Gym to provide them with highquality equipment and customer service. Talwalkars expectation of around 30% growth in its business provides growth visibility for Cravatex. Owing to robust organic growth and strategic partnerships the net revenue for the fitness equipment segment is expected to grow at 45% CAGR over FY2011-14E.
Financials
Key assumptions
Revenue from the sportswear segment is expected to grow at a CAGR of 67% over FY2011-14E, owing to acquisition of the sub-license for distribution through specified channels in the UK and Ireland. It is also expected that the retail-led approach of FILA along with governments reform to allow up to 51% FDI in the retail sector will together enhance the companys earnings. In case of the fitness equipment segment, revenue is expected to grow at a CAGR of 45% over FY2011-14E on the back of expansion plans of health club chains such as Talwalkars and Gold Gym, with whom the company has signed strategic partnerships. Also, Cravatex plans to expand its existing network of retail stores, which will provide it greater visibility among retail consumers.
EBITDA (LHS)
Net profit of the company is expected to grow at a CAGR of 39% over FY2011-14E, from `6.4cr in FY2011 to `17.2cr in FY2014E.
Risks
High cost of equipment
India does not have quality equipment manufacturers due to which majority of the equipment are been imported (largely from USA). The duty structure on imported equipment is around 23%. Thus, considering the original cost of fitness equipment, imports duty inflates their cost, which further leads to higher fixed cost for consumers both individuals and institutions.
Euro slowdown
Subsidiary in UK which, Cravatex has recently acquired is expected to deliver potential annual revenue of around 10mn for coming two years. This revenue potential may be adversely impacted due to recent slowdown in Euro zone.
Currency Impact
Cravatex imports most of its equipment from outside country. Rupee depreciation will make the imports expensive and increase the cost of acquiring the equipment. High procurement cost will thereby impact the margins of the company.
Sportswear industry
The sportswear industry in India includes sports apparel, sports footwear and accessories. The market for premium sports apparel and footwear industry in India is currently worth `2,500cr as specified by the management. On the back of mounting popularity of sports, higher disposable income and changing lifestyle and consumer preferences, the sports apparel and footwear industry is expected to grow at 15% CAGR over FY2011-14 as per the companys estimations. Increasing number of sports events and activities such as CWG and IPL are providing scope and growth opportunities for players in the industry. The Indian sportswear industry is at a nascent stage with increasing organized retail space. Moreover, the trend of sportswear brand endorsements by prominent celebrities is helping in boosting awareness among people. However, the industry has to cope with price-conscious customers, extensive competition and limited channels for distribution. Key challenges identified in the sportswear industry include poor state of sports infrastructure in the country, imposition of excise duty and competition from unorganized players. Further, competition from organized, international players such as Nike, Adidas, FILA and Reebok continues to grab the industry share of players in the Indian sportswear industry.
Company background
Cravatex mainly operates in two segments a) distribution of fitness equipment and b) distribution of sports footwear and apparel of the brand FILA. Contribution from the sportswear segment to the companys revenue has increased from 24% of the total revenue in FY2007 to 56% in FY2011, while contribution of the fitness segment has reduced from 49% in FY2007 to 40% in FY2011. Cravatex has recently issued bonus shares in the ratio of 1:1 by capitalizing the subsequent amount from the General Reserve account of the company.
FitnessEquipment Segment(40%)
Sportswear Segment(56%)
OtherServices (4%)
ProlineFitness
Distributors
Healthclub chains
Franchisee
Homeuse equipments
Shopinshops
MBO's
10
Y/E March (` cr) Gross sales Less: Excise duty Net Sales Other operating income Total operating income % chg Net Raw Materials (% of Net Sales) Other Mfg costs % chg Personnel % chg Other % chg Total Expenditure EBITDA % chg (% of Net Sales) Depreciation & Amortization EBIT % chg (% of Net Sales) Interest & other charges Other Income (% of Net Sales) Extraordinary Expense/(Inc.) PBT (reported) Tax (% of PBT) PAT (reported) PAT after MI (reported) ADJ. PAT % chg (% of Net Sales) Basic EPS (`) Fully Diluted EPS (`) % chg Dividend Retained Earning
FY2009 FY2010 FY2011 FY2012E 44 44 44 (12.6) 28 62.2 1 48.9 4 0.5 12 2.2 45 (1) (138.1) (2.5) 1 (2) (202.1) (4.4) 1 6 13.2 (0) 3 1 31.2 2 2 2 20.3 4.2 7 7 20.3 0 1 58 58 58 32.2 33 56.8 1 (25.4) 5 19.3 16 31.9 55 3 (378.9) 5.2 1 2 (218.4) 4.0 1 6 9.5 (0) 7 3 47.5 4 4 4 98.7 6.4 14 14 98.7 1 3 93 93 93 58.4 51 54.9 3 159.0 9 84.5 23 42.9 86 7 125.7 7.4 1 6 160.2 6.5 2 5 5.2 9 3 31.4 6 6 6 71.4 6.9 25 25 71.4 1 6 230 230 230 148.5 148 64.5 6 148.7 18 109.1 44 86.1 217 13 91.1 5.7 1 12 100.9 5.3 3 4 1.7 13 4 30.0 9 9 9 46.6 4.1 36 36 46.6 1 8
FY2013E FY2014E 301 301 301 30.7 194 64.4 8 30.7 29 55.2 57 30.7 288 13 (1.7) 4.3 1 12 (1.8) 3.9 2 6 2.1 16 5 30.0 11 11 11 16.7 3.6 42 42 16.7 1 10 361 361 361 20.2 227 62.9 10 20.2 34 20.2 69 20.2 340 21 62.8 5.8 1 20 67.4 5.5 3 8 2.1 25 7 30.0 17 17 17 58.1 4.8 67 67 58.1 1 16
11
12
13
FY2009 FY2010 FY2011 FY2012E FY2013E FY2014E 90.4 61.9 11.3 0.3 4.0 (160.4) 6.0 7 7 11 2 58 (4.4) 0.7 2.3 (6.9) 7.9 0.4 (12.7) (6.7) (10.0) 12.5 2.2 61 67 99 108 0.4 (5.4) (1.6) 45.5 38.0 9.4 0.3 3.1 58.7 5.1 14 14 17 2 69 4.0 0.5 2.2 4.7 3.3 0.5 5.4 6.6 8.9 20.7 3.0 59 70 110 95 0.5 3.1 2.7 26.5 23.4 7.1 0.4 2.0 27.1 4.2 25 25 28 3 92 6.5 0.7 2.3 10.2 6.0 0.7 13.2 13.4 14.9 26.9 4.3 63 81 103 99 0.7 2.5 3.9 18.1 16.3 5.3 0.6 0.8 14.7 3.2 36 36 40 3 124 5.3 0.7 3.9 14.3 7.7 0.7 19.2 20.1 20.5 29.2 9.8 61 72 104 97 0.7 1.8 4.4 15.5 14.2 4.0 0.6 0.6 14.9 2.7 42 42 46 3 162 3.9 0.7 4.4 12.2 7.0 0.5 15.1 16.9 17.5 26.0 11.6 61 72 104 64 0.5 1.7 4.8 9.8 9.2 2.9 0.6 0.5 9.1 2.2 67 67 71 3 225 5.5 0.7 4.3 16.7 7.7 0.4 20.1 23.0 23.9 29.6 12.7 62 72 104 68 0.4 1.0 7.3
14
E-mail: advisory@angelbroking.com
Website: www.angelbroking.com
DISCLAIMER
This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past. Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited and its affiliates may have investment positions in the stocks recommended in this report.
Disclosure of Interest Statement 1. Analyst ownership of the stock 2. Angel and its Group companies ownership of the stock 3. Angel and its Group companies' Directors ownership of the stock 4. Broking relationship with company covered
Cravatex No No No No
Note: We have not considered any Exposure below ` 1 lakh for Angel, its Group companies and Directors
Ratings (Returns):
15